It is widespread even among medical professionals as well as medical historians that the formal term of the general anesthetic that Hanaoka developed is Tsusensan and its alias name is Mafutsusan. Hanaoka himself, however, described it as Mafutsusan in his Nyugan Chikenroku, the case report of the first breast cancer excision under general anesthesia with the anesthetic, and a large number of his disciples all used the term Mafutsusan to denote the anesthetic in their manuscripts. The description of Tsusensan has not been found in the documents written in the Edo period, and this name is detected only in the epitaph of Hanaoka. Consequently, we should refer to Hanaoka's anesththetic as "Mafutsusan, another name Tsusensan" instead of "Tsusensan, another name Mafutsusan."

Download full-text PDF

Source

Publication Analysis

Top Keywords

[seishu hanaoka
4
hanaoka describe
4
anesthetic
4
describe anesthetic
4
anesthetic tsusensan--a
4
tsusensan--a misunderstanding
4
misunderstanding terms
4
mafutsusan
4
terms mafutsusan
4
mafutsusan tsusensan]
4

Similar Publications

Background: The 1-year clinical outcomes of the Absorb GT1 Japan post-market surveillance (PMS) suggested that an appropriate intracoronary imaging-guided bioresorbable vascular scaffold (BVS) implantation technique may reduce the risk of target lesion failure (TLF) and scaffold thrombosis (ST) associated with the Absorb GT1 BVS. The long-term outcomes through 5 years are now available.

Methods and results: This study enrolled 135 consecutive patients (n=139 lesions) with ischemic heart disease in whom percutaneous coronary intervention (PCI) with the Absorb GT1 BVS was attempted.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigated the outcomes of intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) in patients with multivessel disease, focusing on those with different SYNTAX scores (SS).
  • It included 1,005 patients categorized into low (≤22), intermediate (23-32), and high (≥33) SS, assessing the rate of major adverse cardiac and cerebrovascular events (MACCE) after one year.
  • Results showed that patients with high SS had a significantly higher rate of MACCE compared to those with low and intermediate SS, indicating that the severity of coronary disease impacts long-term outcomes post-PCI.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!